Skip to content

Clinical study of 68Ga-FT-FAPI and 18F-FT-FAPI PET/CT and contrast-enhanced CT imaging in the diagnosis, staging, and recurrence monitoring of epithelial derived tumors

Clinical study of 68Ga-FT-FAPI and 18F-FT-FAPI PET/CT and contrast-enhanced CT imaging in the diagnosis, staging, and recurrence monitoring of epithelial derived tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400081230
Enrollment
Unknown
Registered
2024-02-27
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epithelial derived tumors

Interventions

Index test:68Ga-FT-FAPI18F-FT-FAPI PET/CT

Sponsors

the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age = 18 years old; (2) Pathologically diagnosed with epithelial derived tumors, patients who are scheduled for surgical resection/exploration (including primary or recurrent metastatic tumors); (3) Received enhanced CT examination of the lesion site within two weeks; (4) According to the doctor's judgment, the expected survival period is more than 3 months; (5) Voluntary signing of informed consent form; Willing and able to follow the research protocol.

Exclusion criteria

Exclusion criteria: (1) Individuals with a known history of allergies to 68Ga-FT-FAPI and 18F-FT-FAPI and their excipients; (2) Individuals who cannot tolerate intravenous administration methods (such as a history of fainting or bleeding); Researchers believe that imaging examinations such as PET are not suitable or cannot be completed due to special reasons, including claustrophobia, radiation phobia, etc; (3) Patients who have received anti-tumor therapy before examination, or who have received neoadjuvant chemotherapy/targeted therapy for tumor reduction from examination to surgery; (4) Pregnant and lactating women; (5) Practitioners who require long-term exposure to radioactive conditions; (6) Serious diseases such as heart, kidney, lungs, blood vessels, nerves, and mental system, immunodeficiency diseases, and hepatitis/cirrhosis; (7) Participated in other intervention clinical trials within the first month prior to screening; (8) Patients undergoing chemotherapy, immunotherapy, or molecular targeted therapy; (9) There are other situations where the researcher deems it unsuitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
SUVmax;

Countries

China

Contacts

Public ContactFei Kang

the First Affiliated Hospital of the People's Liberation Army Air Force Military Medical University

2326604944@qq.com+86 29 8477 1048

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026